Dendritic Immunotherapy Falters in Phase III RCC Trial – OncLive
OncLive |
Dendritic Immunotherapy Falters in Phase III RCC Trial
OncLive An Independent Data Monitoring Committee (IDMC) has recommended halting the phase III ADAPT trial exploring rocapuldencel-T (AGS-003) for the frontline treatment of metastatic renal cell carcinoma (mRCC), following a futility analysis. Despite this … Argos Therapeutics (ARGS) Says IDMC Recommends Discontinuation of ADAPT Phase 3 Trial of Rocapuldencel-T in … Independent Data Monitoring Committee Recommends Discontinuation of the ADAPT Phase 3 Clinical Trial of … Argos kidney cancer vax fails interim phase 3 futility review |
